Multicenter prospective randomized trial comparing modified Limberg flap transposition and Karydakis flap reconstruction in patients with sacrococcygeal pilonidal disease


Can M. F., Sevinc M. M., HANÇERLİOĞULLARI O., Yilmaz M., Yagci G.

American Journal of Surgery, cilt.200, sa.3, ss.318-327, 2010 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 200 Sayı: 3
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1016/j.amjsurg.2009.08.042
  • Dergi Adı: American Journal of Surgery
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.318-327
  • Anahtar Kelimeler: Pilonidal sinus, Surgical treatment, Closure, Limberg, Karydakis
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background: There is still no consensus as to the optimal treatment for sacrococcygeal pilonidal disease (SPD). Many recommend off-midline closure, if any excisional procedure is to be selected. Methods: The authors prospectively studied 145 patients with SPD who presented at 3 hospitals. Patients were randomly assigned to undergo either modified Limberg flap (MLF) transposition (n = 72) or Karydakis flap reconstruction (n = 73). Surgical findings, complications, recurrence rates, and degree of patient satisfaction, evaluated via a standardized telephone interview, were compared. Results: Operation time was longer in the MLF group. There were no significant differences between the two groups in terms of complication rate, length of stay, or recurrence rate. Patients in the Karydakis group reported feeling completely healed more quickly postoperatively. The two groups reported similar rates of satisfaction. Mandatory patient withdrawal from a given study arm because of the orifice straying from the midline occurred more frequently in the Karydakis group. Conclusions: The MLF technique and the Karydakis procedure appear to generate comparable outcomes. With laterally situated orifices, however, the applicability of the Karydakis method may be limited. © 2010 Elsevier Inc.